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Abstract
Owing to the prominent long-term systemic inflammatory reaction in patients with arthritides and a
growing body of data illustrating that this inflammatory reaction imposes a considerable risk for the
development or aggravation of cardiovascular (CV) disease or overall CV risk, numerous researchers
and clinicians have put enormous effort into the analysis of the effects of risk factors on the course of
CV disease in these patients and the therapeutic options to antagonize progressive atherosclerosis. To
achieve this challenging goal, investigators have shown that all treatment strategies must include the
‘non-rheumatic’ approaches, such as lowering blood pressure, stopping smoking, and improving
metabolic status, in tight association with lowering the overall disease activity of the underlying
rheumaticentity usingantiphlogisticdrugs andconventional as wellasbiologic disease-modifyingdrugs.
Introduction and context
The pathophysiology of all arthritides includes articular
inflammation. In the majority of patients, this is
associated with a continuous vascular flow of proin-
flammatory molecules that are also operative in the
development of vascular lesions that may lead to
atherosclerosis, resulting in a long-term systemic inflam-
matory reaction, and a growing body of data illustrates
that this inflammatory reaction imposes a considerable
risk for the development or aggravation of cardiovascular
(CV) morbidity, which persists independently of the
‘traditional’ risk factors of endothelial dysfunction and
atherosclerosis (as long as the underlying rheumatic
disease is not in remission). A recent systematic review
and meta-analysis of CV mortality in more than 90,000
patients with rheumatoid arthritis (RA) over the course
of 50 years in the pre-biologics era revealed that the
overall pooled standard mortality ratio (SMR) was
calculated as 1.6 and did not change significantly over
time [1]. This observation does not appear to inherit a
regional effect – at least for Europe – as a similar
approach asking the same questions to Swedish patients
[2] also revealed no difference in SMR in the 1978 and
1995 cohorts, although, as noted by the authors, RA
treatment had significantly improved for the later cohort.
In addition, it needs to be noted that, in the CARRE
(CARdiovascular research and RhEumatoid arthritis)
investigation, about one-third of the CV events occurred
prior to the onset of RA and this risk was comparable to
diabetes type 2 patients [3,4].
Basic science data from both cardiology and rheumato-
logy have facilitated detailed molecular insight into the
processes leading to atherosclerosis based on chronic
inflammatory processes. As illustrated in Figure 1,
inflammatory joint diseases and connective tissue
diseases share several of these pathways, including all
cellular components of the vascular and perivascular
compartments [5]. In RA, basically all components of its
pathophysiology, such as proinflammatory cytokines,
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immune system, and circulating autoantibodies, mediate
and promote an accelerated development of athero-
sclerotic lesions in the vascular wall (Figure 2) [6].
Therefore, as outlined below, inflammatory arthritides
such as RA should be considered an additional inde-
pendent risk factor for CV disease and these patients
need to be treated more actively for CV prevention and
risk factor modification, not unlike, for example, patients
with metabolic diseases associated with a high CV risk.
This treatment strategy certainly must include the ‘non-
rheumatic’ standard measures such as lowering blood
pressure (BP), cessation of smoking, and so on.
Furthermore, it has been found that some ‘cardiologic’
drugs have both vasculoprotective and anti-inflamma-
tory effects. For example, statins were shown to improve
endothelial function [7] as well as reduce arterial
stiffness, lipid oxidation, and inflammatory markers in
RA. The TARA (Trial of Atorvastatin in Rheumatoid
Arthritis)study [8]showedthatatorvastatinfor 6months
had a significant effect on lowering inflammatory
markers, and subsequently in a non-RA study, the
Justification for the Use of Statins in Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER)
trial, rosuvastatin treatment in healthy individuals with
Figure 1. Pathophysiologic processes in inflammatory diseases leading to atherosclerotic lesions [5]
The initiation phase is driven by various stimuli, which are frequently based on metabolic dysfunctions and vasculotoxic lifestyle habits. As soon as vascular
lesions are present, several proinflammatory molecules such as cytokines and immune cells contribute to the perpetuation of the progression of the
inflammatory plaque. Finally, this concert of vasculoremodeling factors results in severe reduction in blood flow and development of thrombotic events. HDL,
high-density lipoprotein; IFNg, interferon-gamma; LDL, low-density lipoprotein; LP(a), lipoprotein (a); MCP-1, monocyte chemoattractant protein-1; MIF,
migration inhibitory factor; MMP, matrix metalloproteinase; oxLDL, oxidized low-density lipoprotein; PG, prostaglandin; TF, tissue factor; TNF, tumor
necrosis factor; VCAM-1, vascular cell adhesion molecule-1.
Reproduced from Full et al., 2009 [5]. Copyright © 2009 BioMed Central Ltd.
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elevated C-reactive protein (CRP) (>2 mg/L) was found
to reduce cardiac events by nearly half. The authorsstated
that, although this study excluded patients with chronic
inflammatory autoimmune disease, nearly all RA
patients would have met the inclusion criteria for
JUPITER [9,10].
Similar to the current strategy of treating RA as early as
possible in order to avoid structural damage to the
affected joints, there are convincing data that antagoniz-
ing inflammation early in the course of the disease might
be the key to CV protection. It was shown, for example,
that inflammation predicts accelerated brachial arterial
wall changes in patients with recent-onset RA [11]. Both
flow-mediated dilatation and independent glyceryltrini-
trate-mediated dilatation were significantly lower at
baseline in early-onset RA patients than in controls but
could be improved over the course of 1 year with
antirheumatic treatment. Of note, the age of the patient,
CRP level at initiation of treatment, and CRP level at 1
year were associated with alterations in brachial
responses.
Recent advances
Recommendations of the European Society of Cardiology
As CV diseases are among the most frequent diseases
affecting overall morbidity and mortality worldwide, a
milestone for assessing and improving the overall CV
risk was the work of the task force led by the European
Society of Cardiology (ESC) on general prevention and
management of CV in 2007. The key points that need
to be addressed when managing individuals at risk for
CV are avoidance of tobacco, lowering BP to below
140/90 mm Hg, lowering serum cholesterol to below
200 mg/dL (5 mmol/L) and more specifically LDL
cholesterol to below 100 mg/dL (2.5 mmol/L), weight
reduction, a healthy diet, and physical activity for at
least 30 minutes per day. However, these recommen-
dations for the assessment and management of CV risk
and the respective CV risk score assessment tools such
as the Framingham score and the Systematic Coronary
Risk Evaluation (SCORE) model presented by the ESC
have been developed for the general population and
not specifically for patients with arthritides as an
additional morbidity factor [12-14]. In addition to the
difficulty that many arthritis patients have in achieving
the goal of physical activity without adequate treat-
ment, arthritides (with the exception of a single
mention of osteoarthritis) are not noted in these
recommendations as an individual or aggravating risk
factor per se. However, it has been stated that general
inflammatory reactions reflected by elevation of CRP
need to be taken into account when approaching this
medical problem.
EULAR recommendations
To improve the situation for the practicing rheumato-
logist, the European League against Rheumatism
(EULAR) recently published recommendations for CV
risk management in patients with RA, ankylosing
spondylitis (AS), or psoriatic arthritis (PsA) [15]. The
working group analyzed all available data and proposed
10 recommendations addressing the CV risk manage-
ment in patients with RA, AS, or PsA (Figure 3). Of note,
reflecting the clinically overt inflammation in patients
with RA, the evidence for an increased CV risk was more
prominent for patients with RA and the strength of the
recommendations differed also between RA on the one
hand and AS and PsA on the other.
In RA patients, the absolute risk of CV-related death is
highest for older male patients, whereas the relative risk
is highest for young female patients [16]. The EULAR task
force stated that the excess CV risk in RA is due mainly to
inflammation rather than the conventional risk factors.
In support of this idea, it was found that chronic
inflammatory markers such as CRP were independently
associated with CV mortality and morbidity. As outlined
above, the SMRs range from 1.5 to 1.9, and similar ratios
are suspected for the spondyloarthopathies.
According to the European guidelines of cardiology
societies, risk assessment should follow the SCORE
model and treatment of the non-arthritic non-inflam-
matory risk factors should be performed according to
these recommendations. Statins, angiotensin-converting
enzyme inhibitors, and/or AT-II (angiotensin-II)
blockers – owing to their potential anti-inflammatory
effects – are preferred treatment options to achieve these
goals [8,9,16-19].
Figure 2. All components of rheumatoid arthritis pathophysiology
contribute to the development of cardiovascular disease
IL, interleukin; TNFa, tumor necrosis factor-alpha.
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As mentioned before, laboratory parameters associated
with inflammation or distinct arthritis entities can be
used in managing arthritis patients at risk for CV disease.
C R Pl e v e l s ,i np a r t i c u l a r ,h a v eb e e nf o u n dt ob e
associated with a high CV risk in patients with RA [20].
In addition, the EULAR task force recommended that
clinicians multiply the derived CV risk estimate by 1.5 if
at least two of the following criteria are present: disease
duration of more than 10 years, severe extra-articular
manifestations, and, more specifically, rheumatoid
factor or anti-cyclic citrullinated peptide antibody
positivity (or both) [12].
The basis of anti-inflammatory therapy: corticosteroids
and non-steroidal anti-inflammatory drugs
Corticosteroids are frequently used in rheumatic patients
and may enhance the CV morbidity due to their negative
effects on metabolism (e.g., lipids, glucose, BP, and
obesity). Interestingly, this has been challenged by a
Figure 3. The 10 recommendations for cardiovascular risk management in inflammatory arthritides as outlined by
the European League against Rheumatism (EULAR) task force [15]
ACE, angiotensin-converting enzyme; anti-CCP, anti-cyclic citrullinated peptide; AS, ankylosing spondylitis; AT-II, angiotensin-II; COXIB, cyclooxygenase
inhibitor; CV, cardiovascular; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor;
SCORE, Systematic Coronary Risk Evaluation; TC/HDL, total cholesterol/high-density lipoprotein.
Reproduced from Peters et al., 2010 [15] with permission. Copyright © 2010 BMJ Publishing Group Ltd.
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syndrome did affect 40% of the RA patients in the
study, long-term corticosteroid treatment did not appear
to be associated with a higher prevalence of the
metabolic syndrome in patients with RA [21]. In
addition, corticosteroids not only contribute to the
reduction of overall inflammatory activity but also
have proven to be effective in decreasing the risk of
atherosclerosis and improving glucose intolerance and
dyslipidemia [22,23]. However, more data specifically
addressing the long-term effect of corticosteroids on
alteration of CV risk are needed.
Of interest, although more than 50,000 patients have
been examined for CV risk caused by non-steroidal anti-
inflammatory drugs (NSAIDs), specifically cyclooxygen-
ase-2 (COX-2) inhibitors (known as ‘coxibs’), the EULAR
task force concludes that the role of COX-2 inhibitors
and most other NSAIDs regarding CV risk is not well
established in patients with inflammatory arthritides and
needs further investigation. This statement is based on
the observations that COX-2 inhibitors can exert
prothrombotic effects and that regular use of NSAIDs
may impair the vasculoprotective role of acetyl-salicylic
acid [24,25]. However, a recent analysis did not show a
significant difference in CV risk factors between users and
non-users of NSAIDs or COX-2 inhibitors, respectively,
in a cohort of patients with RA [26].
Novel aspects of disease-modifying antirheumatic
drugs and biologics
Disease-modifying antirheumatic drugs have been
shown to improve the lipid profile in patients with
early active RA [23,27], and most recently it was
demonstrated that methotrexate (MTX) use not only is
associated with a lowered occurrence of the metabolic
syndrome [28] but also appears to specifically reduce
atherosclerosis [29]. As MTX may induce vasculotoxic
hyperhomocysteinemia through a depletion of folic acid
levels, the current recommendation of folic acid supple-
mentation should also be followed to support the
vasculoprotective effects of MTX, although hyperhomo-
cystemia is not the primary reason for folic acid
supplementation.
Since the start of the era of tumor necrosis factor (TNF)
blockers at the beginning of this millennium, the role of
TNF in the development of CV risk in arthritic diseases
has been investigated more closely due to its prominent
role in inflammation. TNF blockers have been found to
be associated with increased high-density lipoprotein-
cholesterol (HDL-c) and improvement of the total
cholesterol/HDL-c ratio during the first few months of
treatment.
When the body of data addressing the effects of TNF
inhibition was reviewed, it was confirmed that TNF
blockers actually have vasculoprotective and cardiopro-
tective effects in arthritis patients on the basis of a good
level of evidence [2,12,30,31]. Of note, an important
aspect of the study of Dixon and Symmons [30] is the
observation that the decrease in CV events was observed
in TNF responders only. A recent analysis of the German
cohort showed a reduction of the CV hazard ratio related
to TNF inhibitor treatment to 0.70, although it needs to
be mentioned that this investigation focused on heart
failure and not primarily on atherosclerotic disease [31].
However, improvement of CV risk load can be
directly visualized by measurement of the inflamma-
tion-associated stiffness, and two current publications
demonstrated an improvement of the arterial stiffness for
etanercept in RA patients and for infliximab in AS
patients [32,33].
Implications for clinical practice
The current data show impressively that reducing
inflammation is one of the most important factors to
prevent arthritis patients from developing an additional
CV disease. Fortunately, the currently used antiphlogis-
tic and antirheumatic drugs support this goal and low
disease activity at the joints results in low atherogenic
activity at the vessels, especially when used early in the
course of the disease [19,23,27-30,32,33]. However, the
key problem for the practicing rheumatologist is the
lack of time to explain the additional general CV risk
factors and their management in addition to the already
time-consuming management of the underlying
arthritic disease. Modification of lifestyle, especially
cessation of smoking, is one of the most difficult goals
to achieve. On the other hand, when improvement of
the course of the rheumatic disease is achieved, the
overall health of the patient will also improve. Thus, the
current evidence for CV medicine in rheumatology can
be summarized as: What is good for the joints is good
for the heart and vice versa!
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